Predicting Poor Outcomes in Nonvariceal Upper Gastrointestinal Bleeding

Comorbidity, age >65 years, history of bleeding ulcers, and source and setting of bleeding contributed to risk for continued or recurrent bleeding, or death within 30 days.

Advances in endoscopic and pharmacologic therapy have reduced the risk for rebleeding in patients with nonvariceal upper gastrointestinal bleeding (UGIB); however, mortality remains relatively unchanged.

To determine the contributors to poor clinical outcomes (persistent/recurrent bleeding or death within 30 days), investigators conducted an industry-sponsored, retrospective cohort study of 2664 patients (mean age, 66.7; 64.7% men) who presented with UGIB (outpatient or inpatient) to any of 123 participating centers in seven European countries during a 2-month period in 2008. Information on patient characteristics, presentation, clinical course, treatment, and outcomes was collected from medical records. Multivariate analysis was performed t…

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose